Restricted G Confidential Halted access





Patent Department - RY 60-30 Merck & Co., Inc. P.O. Box 2000 Rahway, NJ 07065

FACSIMILE COVER SHEET

Date: January 15, 2008

Please deliver the following message to:

Commissioner for Patents

Fax Number:

(571) 273-8300

Phone Number:

(571) 272-0696

Examiner's Name:

Rebecca L. Anderson

Group number:

1626

Phone number:

(571)272-0698

This message is from:

Name:

Fax number: Phone number:

J. Eric Thies (732) 594-4720 (732) 594-3904

RE:

USSN:

10/511,691 October 14, 2004

Filing Date: Applicants' Ref.:

For:

Case 20974YP

PROCESS FOR THE SYNTHESIS OF 5[[2(R)-[1(R)-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHOXYJ-3(S)-(4-FLUOROPHENYL)-4-MORPHOLINYL]-METHYL]1,2-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE

NUMBER OF PAGES BEING TRANSMITTED (INCLUDING COVER):

16

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL (732) 594-1251

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below

Type or print name of person signing certification Christine Dona	
Signature Chapture DOVA	Date 1/15/08

RECEIVED CENTRAL FAX CENTER JAN 1 5 2008

Response under 37 C.F. § 1.116 **Expedited Procedure** Examining Group: 1626

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

David Hands, et al.

Serial No. :

10/511,691

Case No.: 20974YP

. Art Unit:

Filed

October 14, 2004

1626 . Examiner:

Rebecca L. Anderson

For

PROCESS FOR THE SYNTHESIS OF 5[[2(R)-[1(R)-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY]-

3(S)-(4-FLUOROPHENYL)-4-MORPHOLINYL]-METHYL]1,2-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE UNDER 37 C.F.R. §1.116

Sir:

With reference to the Official action of October 15, 2007, for which a response is permitted by January 15, 2008, the Applicants respectfully request reconsideration of the application in view of the following amendments and remarks in the hope that they will place the application in condition for allowance or at least in better condition for appeal. Any additional fees associated with this Response may be charged to Merck Deposit Account No. 13-2755.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this response. Remarks begin on page 6 of this response.